-
Crain’s Grand Rapids Business senior writer Mark Sanchez discusses a Corporate Transparency Act court ruling, Michigan lawmakers considering bills promoting a public-private partnership producing low-cost generic insulin, and the latest U of M economic outlook.
-
The state Supreme Court has agreed to hear arguments in a case regarding Michigan Attorney General Dana Nessel’s desire to investigate alleged insulin price gouging.
-
A Grand Rapids Van Andel Institute researcher has received a federal award for developing a diabetes insulin resistance prevention treatment.
-
Michigan’s U.S. senators are touting the benefits of Medicare price reforms approved by Congress which take effect this week
-
We talk about BHSH System rebranding as Corewell Health, the SOAR fund, and insulin in Michigan
-
A handful of state departments have to figure out ways to lower the cost of insulin in Michigan by mid-December.
-
Lower prescription drug costs, free vaccinations part of new legislation
-
Grand Rapids City Commission sale of 201 Market Avenue S.W. to Grand Rapids-Kent County Convention/Arena Authority
-
“The average out-of-pocket cost of a single vial of insulin is nearly $100,” Nessel, a Democrat, said in a statement. “No Michigander should have to face that kind of cost for life-saving medicine.”
-
AG asked an Ingham County judge to authorize a probe under the state consumer protection law.